(184 days)
P780012, BK960085
No
The device description details a standard immunoassay system using luminescence and competitive binding techniques, with no mention of AI or ML algorithms for data analysis or interpretation.
No.
The device is for in vitro diagnostic (IVD) use and aids in the diagnosis of hepatitis A virus infection or identification of HAV-susceptible individuals. It does not exert a therapeutic effect on the patient.
Yes
The device, VITROS Anti-HAV Total Reagent Pack, is used for the qualitative detection of total antibody to hepatitis A virus, stated as "an aid in the clinical laboratory diagnosis of individuals with acute or past hepatitis A virus infection, or as an aid in the identification of HAV-susceptible individuals prior to HAV vaccination." This directly falls under the definition of a diagnostic device.
No
The device description clearly outlines a system comprised of hardware (VITROS Immunodiagnostic System - instrumentation), reagents (VITROS Immunodiagnostic Products range of immunoassay products, common reagents), and a specific assay technique involving physical components like coated microwells and chemical reactions. This is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the VITROS Anti-HAV Total Reagent Pack is "For the in vitro qualitative detection of total antibody (IgG and IgM) to hepatitis A virus (anti-HAV) in human adult and pediatric serum and plasma...". The calibrator and controls are also described as being for "in vitro use".
- Device Description: The description details how the system uses human body fluids (serum and plasma) and reagents to perform an assay to detect an analyte (anti-HAV antibody). This is a core characteristic of an in vitro diagnostic device.
- Purpose: The assay is intended to be used "as an aid in the clinical laboratory diagnosis of individuals with acute or past hepatitis A virus infection, or as an aid in the identification of HAV-susceptible individuals prior to HAV vaccination." This clearly indicates a diagnostic purpose performed outside of the body.
N/A
Intended Use / Indications for Use
VITROS Anti-HAV Total Reagent Pack:
For the in vitro qualitative detection of total antibody (IgG and IgM) to hepatitis A virus (total anti-HAV) in human adult and pediatric serum or plasma (EDTA, heparin or citrate using the VITROS ECi/ECiQ Immunodiagnostic System.
VITROS Anti-HAV Total Calibrator
For in vitro use in the calibration of the VITROS Immunodiagnostic System for the qualitative detection of antibodies to hepatitis A virus (anti-HAV) in human serum and plasma (EDTA, heparin or citrate).
VITROS Anti-HAV Total Controls
For in vitro use in monitoring the performance of the VITROS Immunodiagnostic System when used for the detection of antibodies to Hepatitis A virus (anti-HAV).
The assay is indicated, in conjunction with other serological and clinical information, as an aid in the clinical laboratory diagnosis of individuals with acute or past hepatitis A virus infection, or as an aid in the identification of HAV-susceptible individuals prior to HAV vaccination. The detection of HAV-specific antibodies in human serum or plasma is laboratory evidence of acute or recent HAV infection.
Product codes (comma separated list FDA assigned to the subject device)
LOL
Device Description
The VITROS Immunodiagnostic System uses luminescence as the signal in the quantitative and semi-quantitative determination of selected analytes in human body fluids, commonly serum and plasma. Coated microwells are used as the solid phase separation system.
The system is comprised of three main elements:
. The VITROS Immunodiagnostic Products range of immunoassay products (in this case the VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack and the VITROS Immunodiagnostic Products Anti-HAV Total Calibrators) and VITROS Immunodiagnostic Products High Sample Diluent B which are combined by the VITROS Immunodiagnostics System to perform the VITROS Anti-HAV Total assay.
. The VITROS Immunodiagnostic System - instrumentation, which provides automated use of the immunoassay kits. The VITROS Immunodiagnostic System was cleared for market by a separate 510(k) pre-market notification (K962919).
. Common reagents used by the VITROS System in each assay. The VITROS Immunodiagnostic Products Signal Reagent and VITROS Immunodiagnostic Products Universal Wash Reagent were cleared as part of the VITROS Immunodiagnostic Products Total T3 Reagent Pack and VITROS Immunodiagnostic Products Total T3 Calibrators 510(k) premarket notification (K964310).
Note: High Sample Diluent B was cleared as part of the VITROS Immunodiagnostic Products Total beta-hCG Reagent Pack and VITROS Immunodiagnostic Products Total beta-hCG Calibrators 510(k) premarket notification (K970894).
The VITROS System and common reagents are dedicated specifically for use only with the VITROS Immunodiagnostic Products range of immunoassay products.
The VITROS Anti-HAV Total assay utilizes a competitive assay design for the measurement of antibody to HAV Total (IgG and IgM). The competitive assay technique is used which involves pre-incubation of anti-HAV in the sample with HAV antigen in the Assay Reagent followed by incubation with a Conjugate Reagent that contains biotinylated mouse monoclonal anti-HAV antibody and horseradish peroxidase (HRP)-labeled mouse monoclonal anti-HAV antibody. The immune complex is captured by streptavidin on the wells, unbound materials are removed by washing. The bound HRP conjugate is measured by a luminescent reaction. A reagent containing luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent, is added to the wells. The HRP in the bound conjugate catalyzes the oxidation of the luminol derivative, producing light. The electron transfer agent (a substituted acetanilide) increases the level of light produced and prolongs its emission. The light signals are read by the VITROS System. The binding of HRP is indicative of the absence anti-HAV antibody.
The VITROS Immunodiagnostic Products Anti-HAV Total Controls is comprised of two levels of human plasma that have been targeted to produce negative or positive results when used with the VITROS Immunodiagnostic Products Anti-HAV Total assay.
Control 1 (Negative)
Anti-HAV negative normal human plasma obtained from donors who were tested individually and found to be negative for hepatitis B surface antigen (HBsAg), and for antibodies to human immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV) using FDA approved methods (enzyme immunoassays, EIA).
Control 2 (Positive)
Normal human plasma spiked with anti-HAV Total positive plasma. Both plasmas were obtained from donors who were tested individually and found to be negative for HBsAg and antibodies to human immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV) using FDA approved methods (EIA).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult and pediatric
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Expected results of the VITROS Anti-HAV Total assay to detect IgG and IgM in presumably healthy individuals were determined from a US population residing in areas of high (Western, US) and low (Eastern US) HAV disease prevalence. The population represented the typical demographics of age, gender and race representative of the United States.
A multi-center study was conducted to establish the performance characteristics of the VITROS Anti-HAV Total assay using samples obtained in the U.S. and India from individuals at high risk for hepatitis and/or with signs or symptoms of hepatitis.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Precision was tested across three sites demonstrating total precision to be less than 6.7%. Precision of serum and plasma were also assessed supporting that there is no substantial difference based on samples matrix. A variety of common interferents and potential cross reactive subgroup were tested supporting that the samples do not interfere with the assay. Both IgG and IgM are detected and immunoglobulin in samples from post HAV vaccination subjects support the assay can be used distinguish an individual as a vaccine candidate.
The overall positive percent agreement among the combined prospective samples was 99.74%. The overall negative percent agreement was 96.49%.
The VITROS Anti-HAV Total assay was positive in 100.0% of samples from subjects known to be anti-HAV IgM reactive. When compared to a reference anti-HAV assay, the percent agreement was 96.1% (74/77) as three subjects were negative for HAV in the reference assay.
The positive percent agreement of samples from pediatric subjects at low risk for hepatitis was 93.75%. The negative percent agreement was 97.85%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Overall positive percent agreement: 99.74%
Overall negative percent agreement: 96.49%
Percent agreement compared to reference anti-HAV assay: 96.1% (74/77)
Positive percent agreement of samples from pediatric subjects at low risk for hepatitis: 93.75%.
Negative percent agreement of samples from pediatric subjects at low risk for hepatitis: 97.85%.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
P780012, BK960085
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3310 Hepatitis A virus (HAV) serological assays.
(a)
Identification. HAV serological assays are devices that consist of antigens and antisera for the detection of hepatitis A virus-specific IgM, IgG, or total antibodies (IgM and IgG), in human serum or plasma. These devices are used for testing specimens from individuals who have signs and symptoms consistent with acute hepatitis to determine if an individual has been previously infected with HAV, or as an aid to identify HAV-susceptible individuals. The detection of these antibodies aids in the clinical laboratory diagnosis of an acute or past infection by HAV in conjunction with other clinical laboratory findings. These devices are not intended for screening blood or solid or soft tissue donors.(b)
Classification. Class II (special controls). The special control is “Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Hepatitis A Virus Serological Assays.” See § 866.1(e) for the availability of this guidance document.
0
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:
1 Submitter Name, Address and Contact
Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, New York 14626-5101 (585) 453-3154
Contact Person: Sarah CV Parsons, RAC
2 Preparation Date
Date 510(k) prepared: March 13, 2006
3 Device Name
VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack VITROS Immunodiagnostic Products Anti-HAV Total Calibrators VITROS Immunodiagnostic Products Anti-HAV Total Controls
Common Name: Anti-HAV Total Assay Anti-HAV Total Controls
Classification Name: Hepatitis A virus (HAV) serological assays (866.3310)
Single (specified) analyte controls (assayed and unassayed (862.1660
Assay Class: II special controls Controls Class: I
4 Predicate Device
The VITROS Immunodiagnostic Products Anti-HAV Total assay is substantially equivalent to the IMX HAVAB 2.0 assay (PMA P780012).
The VITROS Immunodiagnostic Products Anti-HAV Total Controls is substantially equivalent to Blackhawk BioSystems, Inc. Virotrol II (BK960085).
1
5 Device Description
The VITROS Immunodiagnostic System uses luminescence as the signal in the quantitative and semi-quantitative determination of selected analytes in human body fluids, commonly serum and plasma. Coated microwells are used as the solid phase separation system.
The system is comprised of three main elements:
- . The VITROS Immunodiagnostic Products range of immunoassay products (in this case the VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack and the VITROS Immunodiagnostic Products Anti-HAV Total Calibrators) and VITROS Immunodiagnostic Products High Sample Diluent B which are combined by the VITROS Immunodiagnostics System to perform the VITROS Anti-HAV Total assay.
- . The VITROS Immunodiagnostic System - instrumentation, which provides automated use of the immunoassay kits. The VITROS Immunodiagnostic System was cleared for market by a separate 510(k) pre-market notification (K962919).
- . Common reagents used by the VITROS System in each assay. The VITROS Immunodiagnostic Products Signal Reagent and VITROS Immunodiagnostic Products Universal Wash Reagent were cleared as part of the VITROS Immunodiagnostic Products Total T3 Reagent Pack and VITROS Immunodiagnostic Products Total T3 Calibrators 510(k) premarket notification (K964310).
Note: High Sample Diluent B was cleared as part of the VITROS Immunodiagnostic Products Total β-hCG Reagent Pack and VITROS Immunodiagnostic Products Total ß-hCG Calibrators 510(k) premarket notification (K970894).
The VITROS System and common reagents are dedicated specifically for use only with the VITROS Immunodiagnostic Products range of immunoassay products.
The VITROS Anti-HAV Total assay utilizes a competitive assay design for the measurement of antibody to HAV Total (IgG and IgM). The competitive assay technique is used which involves pre-incubation of anti-HAV in the sample with HAV antigen in the Assay Reagent followed by incubation with a Conjugate Reagent that contains biotinylated mouse monoclonal anti-HAV antibody and horseradish peroxidase (HRP)-labeled mouse monoclonal anti-HAV antibody. The immune complex is captured
2
by streptavidin on the wells, unbound materials are removed by washing. The bound HRP conjugate is measured by a luminescent reaction. A reagent containing luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent, is added to the wells. The HRP in the bound conjugate catalyzes the oxidation of the luminol derivative, producing light. The electron transfer agent (a substituted acetanilide) increases the level of light produced and prolongs its emission. The light signals are read by the VITROS System. The binding of HRP is indicative of the absence anti-HAV antibody.
The VITROS Immunodiagnostic Products Anti-HAV Total Controls is comprised of two levels of human plasma that have been targeted to produce negative or positive results when used with the VITROS Immunodiagnostic Products Anti-HAV Total assay.
Control 1 (Negative)
Anti-HAV negative normal human plasma obtained from donors who were tested individually and found to be negative for hepatitis B surface antigen (HBsAg), and for antibodies to human immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV) using FDA approved methods (enzyme immunoassays, EIA).
Control 2 (Positive)
Normal human plasma spiked with anti-HAV Total positive plasma. Both plasmas were obtained from donors who were tested individually and found to be negative for HBsAg and antibodies to human immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV) using FDA approved methods (EIA).
6 Device Intended Use
VITROS Anti-HAV Total Reagent Pack:
For the in vitro qualitative detection of total antibody (IgG and IgM) to hepatitis A virus (total anti-HAV) in human adult and pediatric serum or plasma (EDTA, heparin or citrate using the VITROS ECi/ECiQ Immunodiagnostic System.
VITROS Anti-HAV Total Calibrator
For in vitro use in the calibration of the VITROS Immunodiagnostic System for the qualitative detection of antibodies to hepatitis A virus (anti-HAV) in human serum and plasma (EDTA, heparin or citrate).
VITROS Anti-HAV Total Controls
For in vitro use in monitoring the performance of the VITROS Immunodiagnostic System when used for the detection of antibodies to Hepatitis A virus (anti-HAV).
3
7 Comparison to Predicate Device
The VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack and VITROS Immunodiagnostic Products Calibrators are substantially equivalent to IMX HAVAB 2.0 assay which was approved by FDA (P780012) for IVD use.
4
The VITROS Immunodiagnostic Products Anti-HAV Total Controls is substantially equivalent to Blackhawk BioSystems, Inc Virotrol II which was cleared by FDA (BK960085) for IVD use.
| Similarities | ||
|---|---|---|
| Device | ||
| Characteristic | New Device | Predicate Device |
| Intended Use | For the qualitative | |
| detection of total antibody | ||
| (IgG and IgM) to hepatitis | ||
| A virus (total anti-HAV) | ||
| in serum and plasma | .........is a qualitative | |
| microparticle enzyme | ||
| immunoassay for the | ||
| detection of total antibody | ||
| to hepatitis A virus. | ||
| Basic principle | Enzyme Immuno Assay | Enzyme Immuno Assay |
| Antigen | Hepatitis A virus | Hepatitis A virus |
| Instrumentation | Automated analyzer: ECi | |
| Immunodiagnostic System | Automated analyzer: IMX | |
| System | ||
| Sample type | Serum, plasma (heparin, | |
| citrate, EDTA) | Serum, plasma (heparin, | |
| citrate, EDTA) |
Comparison of the VITROS Immunodiagnostic Products Anti-Table 1.1 HAV Total assay to the IMX HAVAB 2.0 assay: Similarities
Comparison of the VITROS Immunodiagnostic Products Anti-Table 1.2 HAV Total assay to the IMX HAVAB-2.0 assay: Differences
| Differences | ||
|---|---|---|
| Device | ||
| Characteristic | New Device | Predicate Device |
| Antibody | Mouse anti-HAV | |
| monoclonal antibody | Human anti-HAV antibody | |
| Tracer | Horseradish Peroxidase | Alkaline Phosphatase |
| Sample volume | 10μL | 150μL |
5
Table 1.3 Comparison of the VITROS Immunodiagnostic Products Anti-HAV Total Controls to the Blackhawk BioSystems, Inc. Virotrol II Controls: Similarities
| Similarities | ||||
|---|---|---|---|---|
| Device | ||||
| Characteristic | New device | Predicate device | ||
| Intended use | For in vitro use in monitoring | |||
| the performance of the VITROS | ||||
| Immunodiagnostic System when | ||||
| used for the qualitative detection | ||||
| of antibodies to Hepatitis A | ||||
| virus (anti-HAV). | For use with assay | |||
| procedures for the | ||||
| determination of antibodies | ||||
| to Hepatitis A virus (HAV) | ||||
| Matrix of controls | Human plasma and | |||
| antimicrobial agents | Human serum with added | |||
| human proteins and | ||||
| antimicrobial agents |
| Table 1.4 Comparison of the VITROS Immunodiagnostic Products Anti- |
|---|
| HAV Total Controls to the Blackhawk BioSystems, Inc. Virotrol |
| II Controls: Differences |
| Differences | |||
|---|---|---|---|
| Device | |||
| Characteristic | New device | Predicate device | |
| Intended Use | Only for the detection of | ||
| antibodies to HAV | Can be used for the | ||
| determination of antibodies | |||
| to hepatitis B surface | |||
| antigen (HBs) | |||
| Control level | Positive and negative | Positive | |
| Expected values | Each control has a quoted mean | ||
| value derived from a minimum | |||
| of 10 assays and a standard | |||
| deviation anticipated for single | |||
| determinations of each control | |||
| in a number of different | |||
| laboratories using different | |||
| reagent lots. Values are lot | |||
| specific. | There is no assigned value. | ||
| The VIROTROL II reagents | |||
| have been designed to | |||
| produce a positive reaction | |||
| when used in the proper | |||
| manner with many | |||
| commercial test kits. |
.
6
Precision was tested across three sites demonstrating total precision to be less than 6.7%. Precision of serum and plasma were also assessed supporting that there is no substantial difference based on samples matrix. A variety of common interferents and potential cross reactive subgroup were tested supporting that the samples do not interfere with the assay. Both IgG and IgM are detected and immunoglobulin in samples from post HAV vaccination subjects support the assay can be used distinguish an individual as a vaccine candidate.
Expected results of the VITROS Anti-HAV Total assay to detect IgG and IgM in presumably healthy individuals were determined from a US population residing in areas of high (Western, US) and low (Eastern US) HAV disease prevalence. The population represented the typical demographics of age, gender and race representative of the United States.
A multi-center study was conducted to establish the performance characteristics of the VITROS Anti-HAV Total assay using samples obtained in the U.S. and India from individuals at high risk for hepatitis and/or with signs or symptoms of hepatitis.
The overall positive percent agreement among the combined prospective samples was 99.74%. The overall negative percent agreement was 96.49%.
The VITROS Anti-HAV Total assay was positive in 100.0% of samples from subjects known to be anti-HAV IgM reactive. When compared to a reference anti-HAV assay, the percent agreement was 96.1% (74/77) as three subjects were negative for HAV in the reference assay.
The positive percent agreement of samples from pediatric subjects at low risk for hepatitis was 93.75%. The negative percent agreement was 97.85%.
8 Conclusions
The VITROS Immunodiagnostic Products Anti-HAV Total assay was compared to the Abbott IMX HAVAB 2.0 assay testing commercially available reagents and human samples.
The data presented in the premarket notification provide a reasonable assurance that the VITROS Anti-HAV Total assay and the VITROS Anti-HAV Total Controls are safe and effective for the stated intended use and is substantially equivalent to the cleared predicate devices.
7
Image /page/7/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Sarah Parsons Manager, Regulatory Affairs Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive MC0881 Rochester, NY 14626-5101
SEP 1 4 2006
Re: K060678
Trade/Device Name: VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack VITROS Immunodiagnostic Products Anti-HAV Total Calibrators VITROS Immunodiagnostic Products Anti-HAV Total Controls Regulation Number: 21 CFR 866.3310 Regulation Name: Hepatitis A virus (HAV) serological assays Regulatory Class: Class II Product Code: LOL Dated: August 4, 2006 Received: August 7, 2006
Dear Ms. Parsons:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
8
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, attorn
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
9
Page 1 of 1
510(k) Number (if known):
Device Name:
VITROS Immunodiagnostic Products Anti-HAV Total Reagent Pack
VITROS Immunodiagnostic Products Anti-HAV Total Calibrators
VITROS Immunodiagnostic Products Anti-HAV Total Controls
Indications for Use:
VITROS Anti-HAV Total Reagent Pack:
1 060678
For the in vitro qualitative detection of total antibody (IgG and IgM) to hepatitis A virus (anti-HAV) in human adult and pediatric serum and plasma (EDTA, heparin or citrate) using the VITROS ECi/ECiQ Immunodiagnostic System.
The assay is indicated, in conjunction with other serological and clinical information, as an aid in the clinical laboratory diagnosis of individuals with acute or past hepatitis A virus infection, or as an aid in the identification of HAV-susceptible individuals prior to HAV vaccination. The detection of HAV-specific antibodies in human serum or plasma is laboratory evidence of acute or recent HAV infection.
VITROS Anti-HAV Total Calibrator
For in vitro use in the calibration of the VITROS Immunodiagnostic System for the qualitative detection of antibodies to hepatitis A virus (anti-HAV) in human serum and plasma (EDTA, heparin or citrate).
VITROS Anti-HAV Total Controls
For in vitro use in monitoring the performance of the VITROS Immunodiagnostic System when used for the detection of antibodies to Hepatitis A virus (anti-HAV).
Prescription Usc _____________________________________________________________________________________________________________________________________________________________ X (Per 21 CFR 801 Subpart D)
Over-The-Counter Use AND/OR (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
| Division Sign-Off | |
|---|---|
| ------------------- | -- |
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K060673